In the race to forge the next Keytruda from PD-(L)1xVEGF bispecific antibodies, Pfizer and the BioNTech-Bristol Myers Squibb alliance are split on how to position overall survival—the gold-standard oncology endpoint—in their first-line non-small cell lung cancer clinical trials.
- Home |
- In next-gen IO race in NSCLC, BioNTech/BMS and Pfizer are divided on overall survival approach
In next-gen IO race in NSCLC, BioNTech/BMS and Pfizer are divided on overall survival approach
- May 30, 2026
Recent Posts
- LNG market tightens into winter as Europe pulls US cargoes, China reopens contract talks
- EIA: US crude oil inventories down 3.2 million bbl
- Chevron restructures Bakken midstream agreements, transfers Hess Midstream stake
- Cenovus to build oil sands business via Athabasca acquisition
- Centalion acquires Haynesville gas assets from Silver Hill
